نتایج جستجو برای: ticagrelor
تعداد نتایج: 1574 فیلتر نتایج به سال:
Ticagrelor is an oral antiplatelet agent that has been approved for preventing de novo and recurrent acute coronary syndrome. To date, only a few studies have attempted to clarify population differences in the pharmacokinetics pharmacodynamics of ticagrelor between Caucasians Asians. Our aim was develop simple quantification method its pharmacologically active metabolite M8 (AR-C124910XX) human...
BACKGROUND We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (e.g., cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thro...
Volume 88, Number 12 www.aafp.org/afp American Family Physician 821 Ticagrelor (Brilinta) is a newer, reversible P2Y12 platelet inhibitor. Older, irreversible P2Y12 receptor inhibitors include prasugrel (Effient), clopidogrel (Plavix), and ticlopidine. Ticagrelor is labeled for the prevention of vascular events and death in patients with acute coronary syndrome.1 STEPS new drug reviews cover Sa...
Ticagrelor (Brilinta) for acute coronary syndrome.
The PLATO trial revealed a remarkable advantage of ticagrelor over clopidogrel in ACS patients. Unless the regulatory authorities discover serious flaws with the study, which is unlikely, the drug may substantially change the present landscape of oral antiplatelet therapy, especially in high-risk patients. Despite a somewhat unfavourable safety profile, ticagrelor has a lot of room to compensat...
Thienopyridines are a class of drug targeting the platelet adenosine diphosphate (ADP) 2 receptor. They significantly reduce platelet activity and are therefore clinically beneficial in settings where platelet activation is a key pathophysiological feature, particularly myocardial infarction. Ticlopidine, the first of the class introduced to clinical practice, was soon challenged and almost com...
A simple, rapid, accurate and precise stability-indicating HPLC method was developed and validated for the determination of Ticagrelor in bulk and its tablet dosage forms. Separation of the drug was achieved on Hypersil BDS C18 column (100 mm x 4.6 mm, 5 μ) as stationary phase with mobile phase consisting of phosphate buffer pH 3.0 and acetonitrile in the ratio of 70: 30 V/V. The method showed ...
INTRODUCTION Ticagrelor, the first direct-acting, reversibly binding oral P2Y12 receptor antagonist, appears to have a favorable efficacy and safety profile. AIMS To update the evidence and provide an overview of the available data on ticagrelor. EVIDENCE REVIEW Peer reviewed articles published and listed under Medline Search, and published updated guidelines for pharmacotherapies in acute ...
The 2016 American Heart Association/American College of Cardiology guidelines advise the use of dual antiplatelet agents for patients with acute coronary syndrome (ACS) (1). Ticagrelor is a reversible oral antagonist of the ADP receptor P2Y12. It is rapidly absorbed and metabolized by cytochrome P450 (CYP) 3A4. Therefore, ticagrelor suggests a potential for drug interactions with other CYP3A4 s...
AIMS Ticagrelor reduced major adverse cardiovascular event (MACE) by 15-16% in patients with prior myocardial infarction (MI) in PEGASUS-TIMI 54. We hypothesized that patients who recently discontinued P2Y12 inhibition, even years after MI, may be at particular risk of MACE and may derive particular benefit from continuation or reinitiation of therapy. METHODS AND RESULTS Patients in PEGASUS-...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید